Immunization of NHPs with FimH-DSG TM combined with a liposomal QS21/MPLA adjuvant elicited high levels of serum FimH IgG and adhesin blocking antibodies and led to a significant reduction in bacteriuria as well as biomarkers of UTI post-challenge (e.g., IL-8, myeloperoxidase). The gene discussed is CXCL8; the disease is bacterial urinary tract infection.